Literature DB >> 35947165

Immune phenotypes and checkpoint molecule expression of clonally expanded lymph node-infiltrating T cells in classical Hodgkin lymphoma.

Alexej Ballhausen1, Amin Ben Hamza1, Carlotta Welters1, Kerstin Dietze1, Lars Bullinger1,2,3, Hans-Peter Rahn4, Sylvia Hartmann5, Martin-Leo Hansmann6,7, Leo Hansmann8,9,10.   

Abstract

Lymph node-infiltrating T cells have been of particular interest in classical Hodgkin lymphoma (cHL). High rates of complete therapeutic responses to antibody-mediated immune checkpoint blockade, even in relapsed/refractory patients, suggest the existence of a T cell-dominated, antigen-experienced, functionally inhibited and lymphoma-directed immune microenvironment. We asked whether clonally expanded T cells (1) were detectable in cHL lymph nodes, (2) showed characteristic immune phenotypes, and (3) were inhibited by immune checkpoint molecule expression. We applied high-dimensional FACS index sorting and single cell T cell receptor αβ sequencing to lymph node-infiltrating T cells from 10 treatment-naïve patients. T cells were predominantly CD4+ and showed memory differentiation. Expression of classical immune checkpoint molecules (CTLA-4, PD-1, TIM-3) was generally low (< 12.0% of T cells) and not different between CD4+ and CD8+ T cells. Degrees of clonal T cell expansion varied between patients (range: 1-18 expanded clones per patient) and was almost exclusively restricted to CD8+ T cells. Clonally expanded T cells showed non-naïve phenotypes and low checkpoint molecule expression similar to non-expanded T cells. Our data suggest that the therapeutic effects of immune checkpoint blockade require mechanisms in addition to dis-inhibition of pre-existing lymphoma-directed T cell responses. Future studies on immune checkpoint blockade-associated effects will identify molecular T cell targets, address dynamic aspects of cell compositions over time, and extend their focus beyond lymph node-infiltrating T cells.
© 2022. The Author(s).

Entities:  

Keywords:  Hodgkin lymphoma; Immune checkpoint blockade; Lymph node-infiltrating T cells; Lymphoma immunology; Single cell technologies; T cell receptor sequencing

Year:  2022        PMID: 35947165     DOI: 10.1007/s00262-022-03264-8

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.630


  24 in total

1.  Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients.

Authors:  Maher K Gandhi; Eleanore Lambley; Jaikumar Duraiswamy; Ujjwal Dua; Corey Smith; Suzanne Elliott; Devinder Gill; Paula Marlton; John Seymour; Rajiv Khanna
Journal:  Blood       Date:  2006-06-06       Impact factor: 22.113

2.  Linking T-cell receptor sequence to functional phenotype at the single-cell level.

Authors:  Arnold Han; Jacob Glanville; Leo Hansmann; Mark M Davis
Journal:  Nat Biotechnol       Date:  2014-06-22       Impact factor: 54.908

3.  FACS single cell index sorting is highly reliable and determines immune phenotypes of clonally expanded T cells.

Authors:  Livius Penter; Kerstin Dietze; Lars Bullinger; Jörg Westermann; Hans-Peter Rahn; Leo Hansmann
Journal:  Eur J Immunol       Date:  2018-04-03       Impact factor: 5.532

4.  Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma.

Authors:  Tomohiro Aoki; Lauren C Chong; Katsuyoshi Takata; Katy Milne; Monirath Hav; Anthony Colombo; Elizabeth A Chavez; Michael Nissen; Xuehai Wang; Tomoko Miyata-Takata; Vivian Lam; Elena Viganò; Bruce W Woolcock; Adèle Telenius; Michael Y Li; Shannon Healy; Chanel Ghesquiere; Daniel Kos; Talia Goodyear; Johanna Veldman; Allen W Zhang; Jubin Kim; Saeed Saberi; Jiarui Ding; Pedro Farinha; Andrew P Weng; Kerry J Savage; David W Scott; Gerald Krystal; Brad H Nelson; Anja Mottok; Akil Merchant; Sohrab P Shah; Christian Steidl
Journal:  Cancer Discov       Date:  2019-12-19       Impact factor: 39.397

5.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

Review 6.  Biology of Hodgkin's lymphoma.

Authors:  R Küppers; I Schwering; A Bräuninger; K Rajewsky; M L Hansmann
Journal:  Ann Oncol       Date:  2002       Impact factor: 32.976

7.  Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma.

Authors:  Neil A Marshall; Linsey E Christie; Laura R Munro; Dominic J Culligan; Peter W Johnston; Robert N Barker; Mark A Vickers
Journal:  Blood       Date:  2003-11-06       Impact factor: 22.113

8.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

9.  Localization-associated immune phenotypes of clonally expanded tumor-infiltrating T cells and distribution of their target antigens in rectal cancer.

Authors:  Livius Penter; Kerstin Dietze; Julia Ritter; Maria Fernanda Lammoglia Cobo; Josefin Garmshausen; Felix Aigner; Lars Bullinger; Holger Hackstein; Sandra Wienzek-Lischka; Thomas Blankenstein; Michael Hummel; Klaus Dornmair; Leo Hansmann
Journal:  Oncoimmunology       Date:  2019-03-24       Impact factor: 8.110

10.  Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma.

Authors:  Maria A Garcia-Marquez; Martin Thelen; Sarah Reinke; Diandra Keller; Kerstin Wennhold; Jonas Lehmann; Johanna Veldman; Sven Borchmann; Andreas Rosenwald; Stephanie Sasse; Arjan Diepstra; Peter Borchmann; Andreas Engert; Wolfram Klapper; Michael von Bergwelt-Baildon; Paul J Bröckelmann; Hans A Schlößer
Journal:  Leukemia       Date:  2021-09-28       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.